Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Gynecology

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 129 articles: HTML format

Single Articles

June 2021
1. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
   Statin use and survival among women with ovarian cancer: an Australian national data-linkage study.
   Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01460.
   PubMed     Abstract available
   
   
   May 2021
2. XU X, Wang Y, Bryce NS, Tang K, et al
   Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
   Br J Cancer. 2021 May 12. pii: 10.1038/s41416-021-01420.
   PubMed     Abstract available
   
   
   April 2021
3. TIN TIN S, Reeves GK, Key TJ
   Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank.
   Br J Cancer. 2021 Apr 16. pii: 10.1038/s41416-021-01392.
   PubMed     Abstract available
   
   
   
4. BIZZARRI N, Pedone Anchora L, Zannoni GF, Carbone V, et al
   Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study.
   Br J Cancer. 2021 Apr 14. pii: 10.1038/s41416-021-01384.
   PubMed     Abstract available
   
   
   
5. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
   Effects of cancer screening restart strategies after COVID-19 disruption.
   Br J Cancer. 2021;124:1516-1523.
   PubMed     Abstract available
   
   
   March 2021
6. LEPAGE CC, Palmer MCL, Farrell AC, Neudorf NM, et al
   Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
   Br J Cancer. 2021 Mar 17. pii: 10.1038/s41416-021-01317.
   PubMed     Abstract available
   
   
   
7. ZHANG X, Ling MT, Feng H, Wong YC, et al
   Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells.
   Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01322.
   PubMed    
   
   
   
8. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
   The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
   Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
   PubMed     Abstract available
   
   
   
9. SARINK D, Wilkens LR, White KK, Le Marchand L, et al
   Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the Multiethnic Cohort Study.
   Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01292.
   PubMed     Abstract available
   
   
   
10. HALLE MK, Sodal M, Forsse D, Engerud H, et al
    A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01305.
    PubMed     Abstract available
    
    
    February 2021
11. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available
    
    
    
12. CASTANON A, Rebolj M, Pesola F, Sasieni P, et al
    Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01275.
    PubMed     Abstract available
    
    
    
13. HAYASHI T, Konishi I
    Correlation of anti-tumour drug resistance with epigenetic regulation.
    Br J Cancer. 2021;124:681-682.
    PubMed     Abstract available
    
    
    
14. LITWIN TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, et al
    Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.
    Br J Cancer. 2021;124:831-841.
    PubMed     Abstract available
    
    
    January 2021
15. SESTAK I, Blake G, Patel R, Cuzick J, et al
    Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
    Br J Cancer. 2021 Jan 22. pii: 10.1038/s41416-020-01228.
    PubMed     Abstract available
    
    
    
16. LU H, Cunnea P, Nixon K, Rinne N, et al
    Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
    Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01252.
    PubMed     Abstract available
    
    
    
17. BRAGA A, Elias KM, Horowitz NS, Berkowitz RS, et al
    When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
    Br J Cancer. 2021 Jan 8. pii: 10.1038/s41416-020-01209.
    PubMed     Abstract available
    
    
    
18. SALAS-BENITO D, Conde E, Tamayo-Uria I, Mancheno U, et al
    The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes.
    Br J Cancer. 2021 Jan 5. pii: 10.1038/s41416-020-01218.
    PubMed     Abstract available
    
    
    
19. WINFIELD JM, Wakefield JC, Brenton JD, AbdulJabbar K, et al
    Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01217.
    PubMed     Abstract available
    
    
    December 2020
20. PARKER VL, Winter MC, Whitby E, Parker WAE, et al
    Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia.
    Br J Cancer. 2020 Dec 16. pii: 10.1038/s41416-020-01206.
    PubMed     Abstract available
    
    
    
21. CIBULA D, Slama J, Dostalek L, Fischerova D, et al
    Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery.
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01204.
    PubMed     Abstract available
    
    
    
22. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available
    
    
    November 2020
23. KAMAL M, Lameiras S, Deloger M, Morel A, et al
    Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01153.
    PubMed     Abstract available
    
    
    
24. YAN S, Xuan J, Brajanovski N, Tancock MRC, et al
    The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Br J Cancer. 2020 Nov 11. pii: 10.1038/s41416-020-01158.
    PubMed     Abstract available
    
    
    
25. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed     Abstract available
    
    
    October 2020
26. MILLINGTON K, Hayes K, Pilcher S, Roberts S, et al
    A serous borderline ovarian tumour in a transgender male adolescent.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01129.
    PubMed     Abstract available
    
    
    
27. ZHANG Y, Yu M, Jing Y, Cheng J, et al
    Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01123.
    PubMed     Abstract available
    
    
    
28. ARROYO MUHR LS, Lagheden C, Lei J, Eklund C, et al
    Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR.
    Br J Cancer. 2020 Oct 6. pii: 10.1038/s41416-020-01111.
    PubMed     Abstract available
    
    
    September 2020
29. KIM HS, Park SY, Park CY, Kim YT, et al
    A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
    Br J Cancer. 2020 Sep 30. pii: 10.1038/s41416-020-01098.
    PubMed     Abstract available
    
    
    
30. VOSS MH, Gordon MS, Mita M, Rini B, et al
    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Br J Cancer. 2020 Sep 11. pii: 10.1038/s41416-020-01041.
    PubMed     Abstract available
    
    
    
31. MO XT, Leung TH, Tang HW, Siu MK, et al
    CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
    Br J Cancer. 2020;123:833-843.
    PubMed     Abstract available
    
    
    August 2020
32. PHELPS DL, Saso S, Ghaem-Maghami S
    Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies.
    Br J Cancer. 2020 Aug 24. pii: 10.1038/s41416-020-01035.
    PubMed     Abstract available
    
    
    
33. YANG M, Zhang G, Wang Y, He M, et al
    Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.
    Br J Cancer. 2020 Aug 11. pii: 10.1038/s41416-020-1026.
    PubMed     Abstract available
    
    
    
34. KYRGIOU M, Arbyn M, Bergeron C, Bosch FX, et al
    Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC).
    Br J Cancer. 2020;123:510-517.
    PubMed     Abstract available
    
    
    July 2020
35. O'MARA TA, Crosbie EJ
    Polygenic risk score opportunities for early detection and prevention strategies in endometrial cancer.
    Br J Cancer. 2020 Jul 6. pii: 10.1038/s41416-020-0959.
    PubMed     Abstract available
    
    
    
36. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    PubMed     Abstract available
    
    
    June 2020
37. MARTINS FC, Couturier DL, Paterson A, Karnezis AN, et al
    Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
    Br J Cancer. 2020 Jun 18. pii: 10.1038/s41416-020-0900.
    PubMed     Abstract available
    
    
    
38. VAN WEELDEN WJ, van der Putten LJM, Inda MA, van Brussel A, et al
    Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.
    Br J Cancer. 2020 Jun 8. pii: 10.1038/s41416-020-0925.
    PubMed     Abstract available
    
    
    May 2020
39. JIANG YX, Siu MK, Wang JJ, Mo XT, et al
    Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-kappaB/IL-8 signalling in ovarian cancer.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0865.
    PubMed     Abstract available
    
    
    
40. BOCHNER F, Fellus-Alyagor L, Ketter D, Golani O, et al
    Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0878.
    PubMed     Abstract available
    
    
    
41. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    PubMed     Abstract available
    
    
    
42. LEI J, Ploner A, Lehtinen M, Sparen P, et al
    Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Br J Cancer. 2020 May 4. pii: 10.1038/s41416-020-0850.
    PubMed     Abstract available
    
    
    April 2020
43. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0849.
    PubMed     Abstract available
    
    
    
44. JEDY-AGBA E, Joko WY, Liu B, Buziba NG, et al
    Trends in cervical cancer incidence in sub-Saharan Africa.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0831.
    PubMed     Abstract available
    
    
    
45. MONTFORT A, Owen S, Piskorz AM, Supernat A, et al
    Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    Br J Cancer. 2020 Apr 6. pii: 10.1038/s41416-020-0822.
    PubMed     Abstract available
    
    
    
46. ZHAO Y, He M, Cui L, Gao M, et al
    Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0825.
    PubMed     Abstract available
    
    
    
47. HASHIM D, Engesaeter B, Baadstrand Skare G, Castle PE, et al
    Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0790.
    PubMed     Abstract available
    
    
    
48. ARBYN M, Rezhake R, Yuill S, Canfell K, et al
    Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0787.
    PubMed     Abstract available
    
    
    March 2020
49. JEON KH, Shin DW, Han K, Kim D, et al
    Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study.
    Br J Cancer. 2020 Mar 17. pii: 10.1038/s41416-020-0789.
    PubMed     Abstract available
    
    
    February 2020
50. MASOODI T, Siraj S, Siraj AK, Azam S, et al
    Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.
    Br J Cancer. 2020 Feb 26. pii: 10.1038/s41416-020-0763.
    PubMed     Abstract available
    
    
    
51. BERG HF, Ju Z, Myrvold M, Fasmer KE, et al
    Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0745.
    PubMed     Abstract available
    
    
    
52. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    PubMed     Abstract available
    
    
    January 2020
53. HASEGAWA K, Shimada M, Takeuchi S, Fujiwara H, et al
    A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0734.
    PubMed     Abstract available
    
    
    
54. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    PubMed     Abstract available
    
    
    
55. HORIKAWA N, Abiko K, Matsumura N, Baba T, et al
    Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0725.
    PubMed     Abstract available
    
    
    
56. LIU N, Lin X, Huang C
    Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance.
    Br J Cancer. 2020;122:279-292.
    PubMed     Abstract available
    
    
    December 2019
57. GENESTIE C, Blanc-Durand F, Auguste A, Pautier P, et al
    Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0687.
    PubMed     Abstract available
    
    
    
58. SIVALINGAM VN, Latif A, Kitson S, McVey R, et al
    Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0627.
    PubMed     Abstract available
    
    
    
59. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    PubMed     Abstract available
    
    
    November 2019
60. TUNA M, Ju Z, Yoshihara K, Amos CI, et al
    Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
    Br J Cancer. 2019 Nov 29. pii: 10.1038/s41416-019-0654.
    PubMed     Abstract available
    
    
    
61. ANNETT S, Moore G, Short A, Marshall A, et al
    FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
    Br J Cancer. 2019 Nov 27. pii: 10.1038/s41416-019-0649.
    PubMed     Abstract available
    
    
    October 2019
62. HAMESTER F, Legler K, Wichert B, Kelle N, et al
    Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.
    Br J Cancer. 2019 Oct 29. pii: 10.1038/s41416-019-0607.
    PubMed     Abstract available
    
    
    September 2019
63. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available
    
    
    
64. COLOMBO N, Zaccarelli E, Baldoni A, Frezzini S, et al
    Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2019 Sep 20. pii: 10.1038/s41416-019-0584.
    PubMed     Abstract available
    
    
    August 2019
65. TASSI RA, Gambino A, Ardighieri L, Bignotti E, et al
    FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
    Br J Cancer. 2019 Aug 22. pii: 10.1038/s41416-019-0553.
    PubMed     Abstract available
    
    
    
66. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Correction: Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Aug 9. pii: 10.1038/s41416-019-0545.
    PubMed     Abstract available
    
    
    
67. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0544.
    PubMed     Abstract available
    
    
    
68. SHI T, Jiang R, Pu H, Yang H, et al
    Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Br J Cancer. 2019 Aug 6. pii: 10.1038/s41416-019-0543.
    PubMed     Abstract available
    
    
    July 2019
69. LEVASSEUR N, Chia S
    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?
    Br J Cancer. 2019;121:1-2.
    PubMed     Abstract available
    
    
    
70. BERNDSEN RH, Castrogiovanni C, Weiss A, Rausch M, et al
    Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.
    Br J Cancer. 2019;121:139-149.
    PubMed     Abstract available
    
    
    June 2019
71. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Jun 26. pii: 10.1038/s41416-019-0497.
    PubMed     Abstract available
    
    
    
72. QIAN F, Rookus MA, Leslie G, Risch HA, et al
    Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2019 Jun 19. pii: 10.1038/s41416-019-0492.
    PubMed     Abstract available
    
    
    
73. PLUMMER C, Michael A, Shaikh G, Stewart M, et al
    Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Br J Cancer. 2019 Jun 11. pii: 10.1038/s41416-019-0481.
    PubMed     Abstract available
    
    
    April 2019
74. REIJNEN C, van Weelden WJ, Arts MSJP, Peters JP, et al
    Poor outcome in hypoxic endometrial carcinoma is related to vascular density.
    Br J Cancer. 2019 Apr 23. pii: 10.1038/s41416-019-0461.
    PubMed     Abstract available
    
    
    
75. HORN J, Denecke A, Luyten A, Rothe B, et al
    Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.
    Br J Cancer. 2019 Apr 16. pii: 10.1038/s41416-019-0453.
    PubMed     Abstract available
    
    
    March 2019
76. FORTNER RT, Terry KL, Bender N, Brenner N, et al
    Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
    Br J Cancer. 2019 Mar 21. pii: 10.1038/s41416-019-0422.
    PubMed     Abstract available
    
    
    
77. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Mar 19. pii: 10.1038/s41416-019-0425.
    PubMed     Abstract available
    
    
    
78. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2019 Mar 13. pii: 10.1038/s41416-019-0433.
    PubMed     Abstract available
    
    
    February 2019
79. FROELING FEM, Ramaswami R, Papanastasopoulos P, Kaur B, et al
    Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours.
    Br J Cancer. 2019 Feb 22. pii: 10.1038/s41416-019-0402.
    PubMed     Abstract available
    
    
    
80. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Feb 5. pii: 10.1038/s41416-019-0384.
    PubMed     Abstract available
    
    
    January 2019
81. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Abstract available
    
    
    
82. MULATI K, Hamanishi J, Matsumura N, Chamoto K, et al
    VISTA expressed in tumour cells regulates T cell function.
    Br J Cancer. 2019;120:115-127.
    PubMed     Abstract available
    
    
    December 2018
83. SINGEL KL, Grzankowski KS, Khan ANMNH, Grimm MJ, et al
    Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Br J Cancer. 2018 Dec 6. pii: 10.1038/s41416-018-0339.
    PubMed     Abstract available
    
    
    November 2018
84. GILBERT DC, Wakeham K, Langley RE, Vale CL, et al
    Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0273.
    PubMed     Abstract available
    
    
    
85. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
    PubMed     Abstract available
    
    
    October 2018
86. WORTMAN BG, Creutzberg CL, Putter H, Jurgenliemk-Schulz IM, et al
    Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
    Br J Cancer. 2018 Oct 25. pii: 10.1038/s41416-018-0310.
    PubMed     Abstract available
    
    
    
87. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
    PubMed     Abstract available
    
    
    
88. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
    PubMed     Abstract available
    
    
    
89. ARROYO-MUHR LS, Lagheden C, Hultin E, Eklund C, et al
    Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study.
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0311.
    PubMed     Abstract available
    
    
    
90. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    PubMed     Abstract available
    
    
    
91. NIEMI RJ, Braicu EI, Kulbe H, Koistinen KM, et al
    Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
    Br J Cancer. 2018 Oct 8. pii: 10.1038/s41416-018-0270.
    PubMed     Abstract available
    
    
    
92. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Abstract available
    
    
    
93. WILLIAMS LA, Mills L, Hooten AJ, Langer E, et al
    Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0277.
    PubMed     Abstract available
    
    
    August 2018
94. TSIBULAK I, Wieser V, Degasper C, Shivalingaiah G, et al
    BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0217.
    PubMed     Abstract available
    
    
    
95. AOKI Y, Ochiai K, Lim S, Aoki D, et al
    Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
    Br J Cancer. 2018 Aug 3. pii: 10.1038/s41416-018-0206.
    PubMed     Abstract available
    
    
    July 2018
96. GADDUCCI A, Grosso F, Scambia G, Raspagliesi F, et al
    A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0190.
    PubMed     Abstract available
    
    
    
97. CARTER JH, Deddens JA, Mueller G, Lewis TG, et al
    Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0191.
    PubMed     Abstract available
    
    
    
98. KOMMOSS FK, Karnezis AN, Kommoss F, Talhouk A, et al
    L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
    Br J Cancer. 2018 Jul 27. pii: 10.1038/s41416-018-0187.
    PubMed     Abstract available
    
    
    
99. GHAFFARI A, Peterson N, Khalaj K, Vitkin N, et al
    STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Br J Cancer. 2018 Jul 26. pii: 10.1038/s41416-018-0188.
    PubMed     Abstract available
    
    
    
100. HILLIARD C
     Comment on 'Dairy, calcium, vitamin D, and ovarian cancer risk in African-American women'.
     Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0166.
     PubMed    
     
     
     
101. QIN B, Peres LC, Schildkraut JM, Bandera EV, et al
     Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
     Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0163.
     PubMed    
     
     
     June 2018
102. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
     Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
     Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
     PubMed     Abstract available
     
     
     
103. SHI T, Jiang R, Yu J, Yang H, et al
     Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
     Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0036.
     PubMed     Abstract available
     
     
     
104. VIALATTE DE PEMILLE C, Berzero G, Small M, Psimaras D, et al
     Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
     Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0125.
     PubMed     Abstract available
     
     
     
105. ZHENG R, Du M, Zhang B, Xin J, et al
     Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
     Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
     PubMed     Abstract available
     
     
     
106. TUNG NM, Garber JE
     BRCA1/2 testing: therapeutic implications for breast cancer management.
     Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
     PubMed     Abstract available
     
     
     May 2018
107. NEUMEYER S, Banbury BL, Arndt V, Berndt SI, et al
     Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer.
     Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0108.
     PubMed     Abstract available
     
     
     
108. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
     Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
     Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
     PubMed     Abstract available
     
     
     March 2018
109. LAGHEDEN C, Eklund C, Lamin H, Kleppe SN, et al
     Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer.
     Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0053.
     PubMed     Abstract available
     
     
     
110. DIXON-SUEN SC, Nagle CM, Thrift AP, Pharoah PDP, et al
     Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
     Br J Cancer. 2018 Mar 20. pii: 10.1038/s41416-018-0011.
     PubMed     Abstract available
     
     
     
111. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
     Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
     Br J Cancer. 2018;118:733-737.
     PubMed     Abstract available
     
     
     February 2018
112. GUSTAVSSON I, Aarnio R, Berggrund M, Hedlund-Lindberg J, et al
     Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology.
     Br J Cancer. 2018 Feb 13. pii: bjc2017485. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
113. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
     A core matrisome gene signature predicts cancer outcome.
     Br J Cancer. 2018;118:435-440.
     PubMed     Abstract available
     
     
     January 2018
114. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
     Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
     Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
115. VERDOODT F, Kjaer SK, Dehlendorff C, Friis S, et al
     Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.
     Br J Cancer. 2018 Jan 9. pii: bjc2017449. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
116. LAM JUH, Elfstrom KM, Ejegod DM, Pedersen H, et al
     High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
     Br J Cancer. 2018;118:138-144.
     PubMed     Abstract available
     
     
     December 2017
117. PLAYDON MC, Coburn SB, Moore SC, Brinton LA, et al
     Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study.
     Br J Cancer. 2017 Dec 12. pii: bjc2017419. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     November 2017
118. SEAMON LG, Java JJ, Monk BJ, Penson RT, et al
     Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.
     Br J Cancer. 2017 Nov 28. pii: bjc2017400. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
119. HALLE MK, Tangen IL, Berg HF, Hoivik EA, et al
     HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
     Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
120. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
     The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
     Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
121. MARKOVINA S, Wang S, Henke LE, Luke CJ, et al
     Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.
     Br J Cancer. 2017 Nov 7. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     October 2017
122. HEINONEN HR, Mehine M, Makinen N, Pasanen A, et al
     Global metabolomic profiling of uterine leiomyomas.
     Br J Cancer. 2017 Oct 26. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
123. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
     Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
     Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     September 2017
124. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
     Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
     Br J Cancer. 2017;117:1048-1062.
     PubMed     Abstract available
     
     
     
125. WANG X, Zhu Q, Lin Y, Wu L, et al
     Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
     Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     
126. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
     HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.
     Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     
     August 2017
127. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
     Leukocyte telomere length and renal cell carcinoma survival in two studies.
     Br J Cancer. 2017;117:752-755.
     PubMed     Abstract available
     
     
     
128. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
     Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
     Br J Cancer. 2017;117:628-638.
     PubMed     Abstract available
     
     
     
129. BURGER EA, Pedersen K, Sy S, Kristiansen IS, et al
     Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
     Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: